Clinical Trial Update: Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer [Phase 2]

View source ↗

Summary

Phase II neoadjuvant trial of dostarlimab in untreated, resectable Stage III colon cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• JEMPERLI (DOSTARLIMAB)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Colon Cancer Stage III | Phase 2 | Status: RECRUITING